Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

19.64 -0.98 (-4.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 669,225
Open 20.47
Bid (Size) 7.910 (200)
Ask (Size) 20.05 (100)
Prev. Close 20.62
Today's Range 19.50 - 20.62
52wk Range 8.480 - 24.25
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bicara (BCAX) Q4 2025 Earnings Transcript ↗
Bicara (BCAX) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer ↗
Bicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the... 
Via MarketBeat

Performance

YTD
+19.9%
+19.9%
1 Month
-13.6%
-13.6%
3 Month
+9.6%
+9.6%
6 Month
+14.5%
+14.5%
1 Year
+98.4%
+98.4%

More News

Read More
News headline image
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics (NASDAQ:BCAX) Q1 2026 Results Highlight Clinical Progress as EPS Misses Estimates ↗
Via Chartmill
News headline image
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data ↗
Via MarketBeat
News headline image
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara (BCAX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Bicara Therapeutics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Bicara Therapeutics Inc.
Via GlobeNewswire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder. ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics to Participate in Upcoming Investor Conferences
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen
From Bicara Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Bicara Therapeutics Inc. - Common Stock publicly traded?
Yes, Bicara Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Bicara Therapeutics Inc. - Common Stock trade on?
Bicara Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Bicara Therapeutics Inc. - Common Stock?
The ticker symbol for Bicara Therapeutics Inc. - Common Stock is BCAX on the Nasdaq Stock Market
What is the current price of Bicara Therapeutics Inc. - Common Stock?
The current price of Bicara Therapeutics Inc. - Common Stock is 19.64
When was Bicara Therapeutics Inc. - Common Stock last traded?
The last trade of Bicara Therapeutics Inc. - Common Stock was at 06/02/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.